Our Legacy

Esperante Development BV was previously known as Disphar International BV.

Disphar was established in 1994 in The Netherlands by Peter Exler, a pioneer in the generic pharmaceutical industry. In 2001, Disphar was acquired by the Nordic Pharma Group.
Since the early days, Disphar was specialised in the development, registration and industrial commercialisation of pharmaceutical products.

Disphar’s business concept was based on concentrating the complete coordination of all development, registration and manufacturing activities in-house, while contracting out the formulation development and supply operations to a network of external experts. This “virtual” concept has enabled Disphar to engage highly specialised experts in any project and to choose the best locations for the development work.

Major activities were:

  • Development of pharmaceutical products
  • Licensing-out
  • Providing regulatory support, to obtain and maintain Marketing Authorisations
  • Supply of finished dosage forms (finished packs or bulk)
  • QA/QC

Disphar used to offer a broad portfolio of EU quality dossiers resulting from own developments and collaborations with other pharmaceutical companies who desired to benefit from Disphar’s specific expertise and strong European customer base.

Disphar’s customer base still includes all major European generic companies, over 100 national generic players, within and outside Europe, as well as some big pharma and OTC companies.

Our main legacy and still marketed products are:
– Betahistine tablets 8, 16 & 24 mg
– Loperamide orodispersible tablets 2 mg
– Naproxen Sodium tablets 220, 275 & 550 mg.
– Flecainide tablets 50 & 100 mg
– Mesalazine EC tablets 250 & 500 mg

This strong development expertise and Industrial supply know-how were the basis of the newly formed ESPERANTE Development BV.


Tolweg 15
3741 LM Baarn
The Netherlands


(+31) 35 52 80 400



Office Hours

M-F: 8:00 am – 5:00 pm